Molecular Subtypes and the Host in Pancreatic Cancer

Recent Publications

2026

Dreyer SB, Bryce A, Froeling F, Jackson S, Santana L, Dickson EJ, Coats M, McKay C, Holroyd D, Biankin AV, Jamieson NB, Chang DK. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Br J Surg. 2026;113(5).

Pea A, He X, Upstill-Goddard R, Luchini C, Schubert Santana LP, Dreyer S, Duthie F, Jamieson NB, McKay CJ, Dickson EJ, Pulvirenti A, Rebus S, Piccoli P, Sperandio N, Lawlor RT, Milella M, Froeling FEM, Salvia R, Scarpa A, Biankin AV, Wedge DC, Chang DK. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Nat Commun. 2026;17(1).

Laird BJA, Antonuzzo L, Cabrero DS, Esin E, Froeling F, Jordan K, Kekez D, Skipworth R, Schooneman M, Yalçın Ş, Prado CM, Muscaritoli M. Embedding nutrition into routine oncology care: about time? Oncol Rev. 2026:1639494.

2025

Herbert KJ, Upstill-Goddard R, Dreyer SB, Rebus S, Pilarsky C, Debabrata M, Lord CJ, Biankin AV, Froeling FEM, Chang DK. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Br J Cancer. 2025.

Knox JJ, O’Kane G, King D, Laheru D, Habowski AN, Yu K, Perez K, Aguirre AJ, Coyne Z, Harvey H, McLaughlin RA, Jang RW, Grant RC, Elimova EC, Renouf DJ, Fischer S, Duan K, Ramotar S, Jang GH, Zhang A, Devoe CE, Singh H, Pishvaian MJ, Froeling FEM, Saif MW, O’Reilly EM, Tsang ES, Wolpin BM, Wilson JM, Dodd A, Pugh TJ, Ye XY, Gallinger S, Tuveson DA, Notta F, Jaffee EM. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. J Clin Oncol. 2025;43(31):3355-3368.

Kocher HM, Sasieni P, Corrie P, McNamara MG, Sarker D, Froeling FEM, Christie A, Gillmore R, Khan K, Propper D. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer. 2025;25(1):106.

2024

Pea A, He X, Upstill-Goddard R, Luchini C, Santana LPS, Dreyer S, Duthie F, Jamieson NB, McKay CJ, Dickson EJ, Pulvirenti A, Rebus S, Piccoli P, Sperandio N, Lawlor RT, Milella M, Froeling FEM, Salvia R, Scarpa A, Bainkin AV, Wedge DC, Chang DK. Clonal evolutionary analysis reveals patterns of malignant transformation in pancreatic cancer from Intraductal Papillary Mucinous IPMN Neoplasms (IPMN). bioRxiv. 2024:2024.2008.2002.606217.

2023

Bergamini A, Ramaswami R, Froeling F, Papanastasopoulos P, Short D, Aguiar X, Savage PM, Sarwar N, Kaur B, Saso S, Fotopoulou C, Sharma A, Rustin GJS, Seckl M. Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study. Int J Gynecol Cancer. 2023;33(11):1750-1756.

Chung T, Garcia L, Swamynathan MM, Froeling FEM, Trotman LC, Tuveson DA, Lyons SK.Internally Controlled and Dynamic Optical Measures of Functional Tumor Biology. Anal Chem. 2023; 95: 5661–5670

2022

Bryce AS, Dreyer SB, Froeling FEM, Chang DK. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers (Basel). 2022;14:5302

2021

Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, Gregori D, Golan T, Braconi C, Froeling FEM, Milella M, Scarpa A, Pea A, Malleo G, Salvia R, Bassi C, Chang DK, Biankin AV. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. J Clin Oncol. 2021;39: 2617-2631

Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML, Candido J, Balkwill F, Barry ST, Grützmann R, Rahib L; Glasgow Precision Oncology Laboratory,; Australian Pancreatic Cancer Genome Initiative, Johns A, Pajic M, Froeling FEM, Beer P, Musgrove EA, Petersen GM, Ashworth A, Frame MC, Crawford HC, Simeone DM, Lord C, Mukhopadhyay D, Pilarsky C, Tuveson DA, Cooke SL, Jamieson NB, Morton JP, Sansom OJ, Bailey PJ, Biankin AV, Chang DK. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology. 2021;160(1):362-377.

Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, DreyerSB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology. 2021;32:183-196.

Froeling FEM, Casolino R, Pea A, Biankin AV, Chang DK. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. J Clin Med. 2021;10: 149

2020

Brunton H, Caligiuri G, Cunningham R, Upstill-Goddard R, Bailey UM, Garner IM, Nourse C, Dreyer SB, Jones M, Moran-Jones K, Wright DW, Paulus-Hock V, Nixon C, Thomson G, Jamieson NB, McGregor GA, Evers L, McKay CJ, Gulati A, Brough R, Bajrami I, Pettit S, Dziubinski ML, Barry ST, Grützmann R, Brown R, Curry E, Glasgow Precision Oncology Laboratory, Australian Pancreatic Cancer Genome Initiative, Pajic M, Musgrove EA, Petersen G, Shanks E, Ashworth A, Crawford HC, Simeone DM, Froeling FEM, Lord CJ, Mukhopadhyay D, Pilarsky C, Grimmond SE, Morton JP, Sansom OJ, Chang DK, Bailey P, Biankin AV. HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports. 2020;31(6):107625.

Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Flores Figueroa F, O’Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J, Wilson JM, Ho Jang G, Zhang A, Liang SB, Borgida A, Chadwick D, Kalimuthu S, Lungu I, Bartlett JMS, Krzyzanowski PM, Sandhu V, Tiriac H, Froeling FEM, Karasinska JM, Topham JT, Renouf DJ, Schaeffer DF, Jones SJM, Marra MA, Laskin J, Chetty R, Stein LD, Zogopoulos G, Haibe-Kains B, Campbell PJ, Tuveson DA, Knox JJ, Fischer SE, Gallinger S, Notta F. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumour evolution. Nat Genet. 2020;52(2):231-240.

Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN, Goulart MR, Hughes C, Imrali A, Roberts R, Pawula M, Houghton R, Lawrence C, Yogeswaran Y, Mousa K, Coetzee C, Sasieni P, Prendergast A, Propper DJ. Phase I clinical trial repurposing all-trans retinoic acid (ATRA) as a stromal targeting 1 agent for pancreatic cancer (STARPAC). Nat Commun. 2020;11(1):4841.

2019

Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA. Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death. Clin Cancer Res. 2019;25(23):7162-7174.

Froeling FEM, Ramaswami R, Papanastasopoulos P, Kaur B, Sebire NJ, Short D, Fisher RA, Sarwar N, Wells M, Singh K, Ellis L, Horsman JM, Winter MC, Tidy J, Hancock BW, Seckl MJ. Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer. 2019;120(6):587-594.

2018

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O’Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8(9):1112-1129.

Ul-Haq I, Dalla Pria A, Suardi E, Pinato DJ, Froeling FEM, Forni J, Randell P, Bower M. Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma. Med Oncol. 2018;35(4):53.

Froeling FEM, Tuveson DA. Pancreatic cancer foiled by a switch of tumour subtype. Nature. 2018;557(7706):500-501.